LNAI Stock Summary and Trading Ideas (Lunai Bioworks | NASDAQ:LNAI)

Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.

Lunai Bioworks trades on the NASDAQ stock market under the symbol LNAI.

As of August 14, 2026, LNAI stock price declined to $2.22 with 28,825 million shares trading.

LNAI has a beta of 1.04, meaning it tends to be more sensitive to market movements. LNAI has a correlation of 0.01 to the broad based SPY ETF.

LNAI has a market cap of $10.07 million. This is considered a Sub-Micro Cap stock.

The top ETF exchange traded funds that LNAI belongs to (by Net Assets): VXF.

LNAI support price is $1.99 and resistance is $2.49 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LNAI shares will trade within this expected range on the day.